Analysis of cathepsin D in human breast cancer: Usefulness of the processed 31kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients

Breast Cancer Research and Treatment

Volumn 60, Issue 2, 2000, Pages 173-179

  Riley, Lee B ^a   Lange, Marianne K ^a   Browne, Richard J ^a   Cochrane, Peter J ^a   Choi, Ik Joon ^b   Davis, Barbara ^c   Arcona, Stephen ^a   Alhadeff, Jack A ^b  

^a ST LUKE S HOSPITAL   (United States)

^b LEHIGH UNIVERSITY   (United States)

^c Regional Cancer Center   (United States)

Author keywords

Active processed cathepsin D; Breast cancer; Prognostic indicator; Survival analysis

Indexed keywords

CATHEPSIN D; ENZYME PRECURSOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; BREAST DISEASE; CANCER INVASION; CANCER REGRESSION; CARCINOMA IN SITU; CONTROLLED STUDY; ENZYME ACTIVITY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; WESTERN BLOTTING;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CATHEPSIN D; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0034030335     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006394401199     Document Type: Article

References (27)

1. 1. Barett AJ: Cellular proteolysis. An overview. Ann NY Acad Sci 674: 1-15, 1992
2. 2. Leto G, Gebbia N, Rausa L, Tumminello, FM: Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res 12: 235-240, 1992
3. 3. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet J-P, Rochefort H: Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14: 642-650,1996
4. 4. Westley BR and May FEB: Cathepsin D and breast cancer. Eur J Cancer 32A: 15-24, 1996
5. 5. Schultz DC, Bazel S, Wright LM, Tucker S, Lange MK, Tachovsky T, Longo S, Niedbala S, Alhadeff JA: Western blotting and enzymatic activity analysis of cathepsin D in breast cancer and benign breast disease and of normal controls. Cancer Res 54: 48-54, 1994
6. 6. Bazel S, Ferry KV, Shoarinejad F, Laury-Kleintop LD, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA: Analysis of breast tissue cathepsin D isoforms from patients with breast cancer, benign breast disease and from normal controls. Intern J Oncol 5: 847-853, 1994
7. 7. Laury-Kleintop LD, Coronel EC, Lange MK, Tachovsky T, Longo S, Tucker S, Alhadeff JA: Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines. Breast Cancer Res Treat 35: 211-220, 1995
8. 8. Wright LM, Levy ES, Patel NP, Alhadeff JA: Purification and characterization of cathepsin D from normal human breast tissue. J Protein Chem 16: 171-181, 1997
9. 9. Bazel S, Alhadeff JA: Characterization of purified cathepsin D from malignant human breast tissue. Intern J Oncol 14: 315-319, 1999
10. 10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951
11. 11. Kute TE, Grondahl-Hansen J, Shao SM, Long R, Russell G, Brunner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node-negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9-16, 1998
12. 12. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM: Cathepsin-D in primary breast cancer prognostic evaluation involving 2810 patients. Br J Cancer 79: 300-307, 1999
13. 13. Ferno M, Baldetorp B, Borg A, Brouillet JP, Olsson H, Rochefort H, Sellberg G, Sigurdsson H, Killander D: Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 30A: 2042-2048, 1994
14. 14. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenheck SH, Chamness GC, Osborne CK: Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467-474, 1994
15. 15. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H: Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer 29A: 1248-1251, 1993
16. 16. Gohring UJ, Scharl A, Thelen U, Ahr A, Crombach G, Titius BR: Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J Clin Pathol 49: 57-64, 1996
17. 17. Aaltonen M, Lipponen P, Kosma V-M, Aaltomaa S, Syrjanen K: Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res 15: 1033-1038, 1995
18. 18. Okamura K, Kohayashi I, Matsuo K, Kiyoshima T, Yamamoto K, Miyoshi A, Sakai H: Immunohistochemical localization of cathepsin D, proliferating cell nuclear antigen and epidermal growth factor receptor in human breast carcinoma analyzed by computer image analyzer: correlation with histological grade and metastatic behavior. Histopathology 31: 540-548, 1997
19. 19. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, and Morales AR: Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol 27: 890-895, 1996
20. 20. Bevilacqua P, Boracchi P, Gasparini G: Prognostic indicators for early-stage breast carcinoma. Part II: Value of Cathepsin D expression, detected by immunocytochemistry A multiparametric study. Intern J Oncol 5: 559-564, 1994
21. 21. Castiglioni T, Merino MJ, Elsner B, Lah TT, Sloane BF, Emmert Buck MR: Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 25: 857-862, 1994
22. 22. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V-M: Predictive value of c-erbB-2. p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917-922, 1997
23. 23. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visona A, Dante S: Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A: 671-677, 1995
24. 24. Glikman P, Rogozinski A, Mosto J, Pollina A, Garbovesky C, Levy, C: Relationship between cathepsin-D and other prognostic factors in human breast cancer. Tumori 83: 688-691, 1997
25. 25. Gohring U-J, Scharl A, Thelen U, Ahr A, Crombach G: Comparative prognostic value of eathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. Anticancer Res 16: 1011-1017, 1996
26. 26. Nikolic-Vukosavljevic D, Grujic-Adanja G, Nastic-Miric D, Brankovic-Magic M, Jovanovic D, Polit DJ, Milrovic L: Cathepsin D: association between TN-stage and steroid receptor status of breast carcinoma. Tumor Biology 19: 329-334,1998
27. 27. Ardavanis A, Gerakini F, Amanatidou A, Scorilas A, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis, I: Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance. Anticancer Res 17:3665-3670, 1997